false
0001799011
0001799011
2024-05-13
2024-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May
13, 2024
| LUCID
DIAGNOSTICS INC. |
| (Exact
Name of Registrant as Specified in Charter) |
| Delaware |
|
001-40901 |
|
82-5488042 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 360
Madison Avenue, 25th
Floor, New
York, New
York |
|
10017 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (917) 813-1828
| N/A |
| (Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, Par Value $0.001 Per Share |
|
LUCD |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
May 13, 2024, the Company issued a press release announcing financial results for its fiscal quarter ended March 31, 2024 and providing
a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item
7.01. Regulation FD Disclosure.
The
disclosure set forth under Item 2.02 is incorporated herein by reference.
The
information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of
the Company, except as shall be expressly set forth by specific reference in such document.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press release. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated:
May 14, 2024 |
LUCID
DIAGNOSTICS INC. |
| |
|
|
| |
By:
|
/s/
Dennis McGrath |
| |
|
Dennis
McGrath |
| |
|
Chief
Financial Officer |
Exhibit
99.1
Lucid
Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Quarterly
EsoGuard® test volume increased 10 percent
Strengthened
balance sheet following completion of $29.8 million Series B Preferred Stock Offering
MolDX
pre-submission meeting scheduled for July 17, 2024
Conference
call and webcast to be held today, May 13th at 8:30 AM EDT
NEW
YORK, May 13, 2024 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage,
cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”),
today provided a business update for the Company and presented financial results for the three months ended March 31, 2024.
Conference
Call and Webcast
The
webcast will take place on Monday, May 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company’s
website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and
international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid
Diagnostics Business Update” to join.
Following
the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s
website at luciddx.com.
Business
Update Highlights
“I
am very pleased with the excellent progress Lucid has made on multiple fronts during the first quarter and recent weeks and look forward
to exciting very near-term milestones for our business,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive
Officer. “We strengthened our balance sheet closing an approximately $30 million preferred stock financing to long-term investors
that extends our runway well past these milestones. Our EsoGuard commercial execution continues to deliver results as we drive towards
expanded private and public coverage, as well as direct contracting. We look forward to our MolDX pre-submission meeting scheduled for
mid-July where we will have the opportunity to present our now robust clinical evidence base for EsoGuard as we seek coverage under its
Local Coverage Determination (LCD). We believe we have line of sight to Medicare coverage.”
Highlights
from the first quarter and recent weeks:
| |
● |
For
the quarter, EsoGuard® revenue was $1.0M, which was flat compared to 4Q23 and represents a 124 percent annual
increase from 1Q23. |
| |
|
|
| |
● |
Lucid’s
CLIA-certified clinical laboratory performed 2,420 commercial EsoGuard Esophageal DNA Tests in 1Q24, which represents a 10 percent
increase sequentially from 4Q23 and a 31 percent annual increase from 1Q23. |
| |
|
|
| |
● |
Continuous
revenue cycle management improvements, including prior authorization appeals, physician advocacy,
etc., while maintaining stable out-of-network allowed amounts averaging
$1,800. |
| |
|
|
| |
● |
Strengthened
balance sheet by completing $29.8 million Series B Preferred Stock Offering. |
| |
|
|
| |
● |
Peer-reviewed
publication of positive data from landmark National Cancer Institute (NCI)-sponsored clinical validation study of EsoGuard
esophageal precancer testing demonstrating unprecedented early cancer detection. The publication of data strengthens EsoGuard’s
clinical data supporting ongoing engagement to secure commercial and Medicare payor coverage. |
| |
|
|
| |
● |
Secured
July 17, 2024 MolDX pre-submission meeting to review data for technical assessment (TA) seeking EsoGuard coverage under its foundational
Local Coverage Determination (LCD). |
| |
|
|
| |
● |
Robust
pipeline of direct contracting engagements with benefits brokers, third-party administrators, and self-insured entities. |
| |
|
|
| |
● |
Actively
executing on aggressive market access strategy focused on securing medical policy coverage with regional plans in biomarker legislation
states and pilots with national plans. |
Financial
Results
| |
● |
For
the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $11.8 million,
which included stock-based compensation expenses of $0.9 million. GAAP net loss attributable to common stockholders was approximately
$18.1 million or $(0.40) per common share. |
| |
|
|
| |
● |
As
shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on
the Company’s financial results, the Company’s non-GAAP adjusted loss for the three months ended March 31, 2024 was approximately
$9.4 million or $(0.21) per common share. |
| |
|
|
| |
● |
Lucid
had cash and cash equivalents of $24.8 million as of March 31, 2024, compared to $18.9 million as of December 31, 2023. Subsequent
to March 31, 2024, the Company completed an issuance of Convertible Preferred Stock Series B-1 resulting in gross proceeds of approximately
$11.6 million. |
| |
● |
The
unaudited financial results for the three months ended March 31, 2024, were filed with the SEC on Form 10-Q on May 13, 2024, and
available at www.luciddx.com or www.sec.gov. |
Lucid
Non-GAAP Measures
| |
● |
To
supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management
provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include
net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA
for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of
EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP. |
| |
|
|
| |
● |
Non-GAAP
financial measures are presented with the intent of providing greater transparency to the information used by us in our financial
performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information
to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical
financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not
intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to,
the most directly comparable GAAP financial measures. |
| |
|
|
| |
● |
Non-GAAP
financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further
information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management
and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business
outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the
reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value
of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance.
In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods. |
| |
|
|
| |
● |
A
reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for
the three months ended March 31, 2024, and 2023 are as follows: |
Condensed consolidated statements of operations (unaudited)
| (in thousands except per-share amounts) | |
For the three months ended
March 31, | |
| | |
2024 | | |
2023 | |
| | |
| | |
| |
| Revenue | |
$ | 1,001 | | |
$ | 446 | |
| | |
| | | |
| | |
| Operating expenses | |
| 11,793 | | |
| 14,763 | |
| Other (Income) expense | |
| (180 | ) | |
| 1,930 | |
| Net Loss | |
| (10,612 | ) | |
| (16,247 | ) |
| Net income (loss) per common share, basic and diluted | |
$ | (0.40 | ) | |
$ | (0.40 | ) |
| Net loss attributable to common stockholders | |
| (18,108 | ) | |
| (16,247 | ) |
| Preferred Stock dividends and deemed dividends | |
| 7,496 | | |
| — | |
| Net income (loss) as reported | |
| (10,612 | ) | |
| (16,247 | ) |
| Adjustments: | |
| | | |
| | |
| Depreciation and amortization expense1 | |
| 501 | | |
| 612 | |
| Interest expense (income), net2 | |
| (56 | ) | |
| (45 | ) |
| EBITDA | |
| (10,167 | ) | |
| (15,680 | ) |
| | |
| | | |
| | |
| Other non-cash or financing related expenses: | |
| | | |
| | |
| Stock-based compensation expense3 | |
| 933 | | |
| 3,208 | |
| ResearchDx acquisition paid in stock1 | |
| — | | |
| 713 | |
| Change in FV convertible debt2 | |
| (291 | ) | |
| 789 | |
| Offering costs convertible debt2 | |
| — | | |
| 1,186 | |
| Debt extinguishments loss - Senior Secured Convertible Note2 | |
| 167 | | |
| — | |
| Non-GAAP adjusted (loss) | |
$ | (9,358 | ) | |
$ | (9,784 | ) |
| Basic and Diluted shares outstanding | |
| 45,014 | | |
| 40,971 | |
| Non-GAAP adjusted (loss) income per share | |
$ | (0.21 | ) | |
$ | (0.24 | ) |
1
Included in general and administrative expenses in the financial statements.
2
Included in other income and expenses.
3
Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by
category within operating expenses for the non-GAAP Net operating expenses:
Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses
| (in thousands except per-share amounts) | |
For the three months ended
March 31, | |
| | |
2024 | | |
2023 | |
| Cost of revenues | |
$ | 1,656 | | |
$ | 1,338 | |
| Stock-based compensation expense3 | |
| (36 | ) | |
| (19 | ) |
| Net cost of revenues | |
| 1,620 | | |
| 1,319 | |
| | |
| | | |
| | |
| Amortization of intangible assets | |
| 372 | | |
| 505 | |
| | |
| | | |
| | |
| Sales and marketing | |
| 4,194 | | |
| 4,127 | |
| Stock-based compensation expense3 | |
| (350 | ) | |
| (356 | ) |
| Net sales and marketing | |
| 3,844 | | |
| 3,771 | |
| | |
| | | |
| | |
| General and administrative | |
| 4,070 | | |
| 6,900 | |
| Depreciation expense | |
| (129 | ) | |
| (107 | ) |
| RDx Settlement in Stock | |
| — | | |
| (713 | ) |
| Stock-based compensation expense3 | |
| (330 | ) | |
| (2,668 | ) |
| Net general and administrative | |
| 3,611 | | |
| 3,412 | |
| | |
| | | |
| | |
| Research and development | |
| 1,501 | | |
| 1,893 | |
| Stock-based compensation expense3 | |
| (217 | ) | |
| (165 | ) |
| Net research and development | |
| 1,284 | | |
| 1,728 | |
| | |
| | | |
| | |
| Total operating expenses | |
| 11,793 | | |
| 14,763 | |
| Depreciation and amortization expense | |
| (501 | ) | |
| (612 | ) |
| RDx Settlement in Stock | |
| — | | |
| (713 | ) |
| Stock-based compensation expense3 | |
| (933 | ) | |
| (3,208 | ) |
| Net operating expenses | |
$ | 10,359 | | |
$ | 10,230 | |
About
EsoGuard and EsoCheck
Millions
of patients with gastroesophageal reflux disease (GERD) are at risk of developing esophageal precancer and a highly lethal form of esophageal
cancer (“EAC”). Over 80 percent of EAC patients die within five years of diagnosis, making it the second most lethal cancer
in the U.S. The mortality rate is high even in those diagnosed with early stage EAC. The U.S. incidence of EAC has increased 500 percent
over the past four decades, while the incidences of other common cancers have declined or remained flat. In nearly all cases, EAC silently
progresses until it manifests itself with new symptoms of advanced disease. All EAC is believed to arise from esophageal precancer, which
occurs in approximately 5 percent to 15 percent of at-risk GERD patients. Early esophageal precancer can be monitored for progression
to late esophageal precancer which can be cured with endoscopic esophageal ablation, reliably halting progression to cancer.
Esophageal
precancer screening is already recommended by clinical practice guidelines for the millions of GERD patients with multiple risk factors,
including age over 50 years, male sex, White race, obesity, smoking history, and a family history of esophageal precancer or cancer.
Unfortunately, fewer than 10 percent of those recommended for screening undergo traditional invasive endoscopic screening. The profound
tragedy of an EAC diagnosis is that death could likely have been prevented if the at-risk GERD patient had been screened and then undergone
surveillance and curative treatment at the precancer stage.
The
only missing element for a viable esophageal cancer prevention program has been the lack of an easily-accessible, in-office screening
tool that can detect esophageal precancer. Lucid believes EsoGuard, performed on samples collected non-endoscopically with EsoCheck,
is the missing element – the first and only commercially available test capable of serving as a widespread screening tool to prevent
esophageal cancer deaths through the early detection of esophageal precancer in at-risk GERD patients. An updated American College of
Gastroenterology (ACG) clinical practice guideline and an American Gastroenterological Association (AGA) clinical practice update both
endorse non-endoscopic biomarker tests as an acceptable alternative to costly and invasive endoscopy for esophageal precancer screening.
EsoGuard is the only such test currently available in the United States.
EsoGuard
is a Next Generation Sequencing (NGS) based DNA methylation assay performed on surface esophageal cells collected with EsoCheck, which
quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1). The assay was initially evaluated in a 408-patient,
multicenter, case-control study published in Science Translational Medicine and showed greater than 90 percent sensitivity and specificity
at detecting esophageal precancer and cancer.
EsoCheck
is a CE Marked and FDA 510(k) cleared noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal
cells in a less than three-minute office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone
catheter from which a soft silicone balloon with textured ridges emerges to gently swab surface esophageal cells. When vacuum suction
is applied, the balloon and sampled cells are pulled into the capsule, protecting them from contamination and dilution by cells outside
of the targeted region during device withdrawal. Lucid believes this proprietary Collect+Protect™ technology makes EsoCheck the
only noninvasive esophageal cell collection device capable of such anatomically targeted and protected sampling. The sample is sent by
overnight express mail to Lucid’s CLIA-certified, CAP-accredited, NYS CLEP approved laboratory, LucidDx Labs, for EsoGuard testing.
About
Lucid Diagnostics
Lucid
Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused
on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.
Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck®
Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer
and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For
more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.
Forward-Looking
Statements
This
press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements
that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics’
management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks
and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics’ common
stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required
to advance Lucid Diagnostics’ products to regulatory submission; whether regulatory authorities will be satisfied with the design
of and results from Lucid Diagnostics’ clinical and preclinical studies; whether and when Lucid Diagnostics’ products are
cleared by regulatory authorities; market acceptance of Lucid Diagnostics’ products once cleared and commercialized; Lucid Diagnostics’
ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict
accurately and many of them are beyond Lucid Diagnostics’ control. In addition, new risks and uncertainties may arise from time
to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may
affect Lucid Diagnostics’ future operations, see Part I, Item 1A, “Risk Factors,” in Lucid Diagnostics’ most
recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A,
“Risk Factors” in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid
Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in
its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the forward-looking statements.
Investor
and Media Contact
Matt
Riley
PAVmed
and Lucid Diagnostics
610.348.8926
mjr@pavmed.com
v3.24.1.1.u2
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Lucid Diagnostics (NASDAQ:LUCD)
Historical Stock Chart
From Apr 2024 to May 2024
Lucid Diagnostics (NASDAQ:LUCD)
Historical Stock Chart
From May 2023 to May 2024
